# Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

> **NCT01788358** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 508 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- **DRUG:** Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

## Key facts

- **NCT ID:** NCT01788358
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-14
- **Primary completion:** 2014-05-01
- **Final completion:** 2014-05-01
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2017-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788358, "Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01788358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*